Taisho's OTC Sales Fall In Japan As Consumers Stay At Home
Executive Summary
A drop in socializing and travelling in Japan due to the COVID-19 pandemic hit demand for Taisho's leading consumer health brands in its latest reporting period.
You may also be interested in...
Takeda Exits Japan's OTC Market With Private-Equity Sale
Takeda is to offload its sizable Japanese OTC operation to private-equity firm Blackstone, which has committed to making the business the country's leading consumer health player.
Japan's Taisho Establishes Global OTC Footprint With $1.6bn Acquisition of Bristol-Myers Squibb's UPSA
Taisho is striking out from its Asian base to create a global OTC player through the acquisition of Bristol-Myers Squibb's UPSA. The transaction will catapult it to the number-three spot in France and give it a foothold in a slew of important emerging markets.
UK Proposes Accelerating Authorizations Of Novel Supplements Like CBD
UK Food Standards Agency proposes shaving a minimum of three months off novel food authorization procedure as part of wider plans to shake-up the process for products like CBD supplements.